Introduction
In myeloma patients the predominant cell type of the malignant clone is the bone marrow plasma cell. Recently B-lymphocytes with immunoglobulin heavy chain gene rearrangements identical to those of the malignant plasma cells (clonally related B-lymphocytes) have been detected with sensitive PCR techniques. It has been suggested that these cells may be precursors of malignant plasma cells. [1] [2] [3] [4] The immunophenotype of clonally related B-lymphocytes is still obscure and this obstructs their isolation and studies concerning their role in myeloma.
Immunoglobulin molecules are composed of heavy and light chains, that in combination form the unique antigen-recognition structure or idiotype. The use of anti-idiotypic anti- bodies (anti-Ids) that specifically detect membrane idiotype expressing B cells is an appealing strategy to isolate clonally related B-lymphocytes. Unfortunately, monoclonal anti-Ids raised by conventional hybridoma techniques frequently cross-react with other idiotypes. [5] [6] [7] [8] [9] Recently, new techniques to obtain immunological reagents have been developed that bypass laborious hybridoma techniques and immunization. The human B cell pool was mimicked by harvesting V gene repertoires from human lymphocytes and cloning them into a vector encoding the major coat protein (gIIIp) from filamentous M13 phages. Phages constructed with immunoglobulin-gIIIp fusion proteins display the immunoglobulin-like domains on their coat. 10 Phage libraries displaying up to 10 12 different single chain antibody fragments (scFv) on their coats are used for in vitro selection of phages reactive with antigens. [10] [11] [12] [13] [14] [15] This paper shows the feasibility of selecting anti-idiotypic scFv bearing phages with high specificity and sensitivity for the monoclonal immunoglobulin produced by myeloma plasma cells.
Materials and methods

Myeloma cell lines and patient material
Myeloma cell lines IM-9, ARH-77, RPMI 8226, U-266, MC-CAR, HS-Sultan (American Type Culture Collection, Rockville, MD, USA), Fravel, UM-1, OPM-1 (gifts of Dr W Vooijs, AZU, Utrecht, The Netherlands) were cultured in RPMI 1640 (Gibco, Paisley, UK) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin (Flow laboratories, Irvine, UK) and 10% heat inactivated FCS (Gibco) in a fully humidified 5% CO 2 atmosphere at 37°C. The bone marrow (BM) mononuclear fraction of three newly diagnosed myeloma patients with stage 3 disease was isolated by FicollHypaque density centrifugation and cryopreserved at −196°C.
Purification of donor polyclonal plasma cells or peripheral blood B-lymphocytes
Plasma cells were isolated from donor BM (obtained after informed consent). Interphase cells were collected from Ficoll-Hypaque density gradients and resuspended in PBS (4 × 10 8 cells/ml) and incubated with 1/10 volume of B-B4 Ab (IQP, Groningen, The Netherlands) at 4°C for 30 min. Cells were then washed and incubated (1 × 10 8 cells/ml) with goat anti-mouse immunomagnetic beads (Dynal, Oslo, Norway) at a 1:2 bead to cell ratio. After 30 min incubation at 4°C cells were selected by magnetic separation and concentrated in 150 l of PBS. Detachment of beads and B-B4 Ab was performed using CD19 Detach-a-Bead (Dynal), a polyclonal antiFab serum according to the manufacturer's protocol. The detached cells were washed and labelled with B-B4-phycoer-ythrin (IQP) and CD38-FITC (Caltag, San Francisco, CA, USA). As control cells were labelled with IgG1-FITC/IgG1-PE. Flow cytometric analysis and cell sorting was performed with an Epics Elite flow cytometer (Coulter, Hialeah, FL, USA), equipped with a 15 mW argon laser. CD38, B-B4 double positive cells were sorted and flow cytometrically re-analyzed to assess the purity. Five thousand sorted cells were cytocentrifuged and staining with May-Grü nwald-Giemsa confirmed plasma cell morphology.
Isolation of B-lymphocytes was essentially identical to the plasma cell isolations. CD19
+ cells were isolated from donor buffy coat mononuclear fractions using 'M450' beads directly coated with 'CD19' antibody (Dynal) added in a 1:2 bead to cell ratio. Flow cytometry (FCM) of selected cells incubated with CD19-PE (Dakopatts, Glostrup, Denmark) revealed Ͼ95% purity.
In vitro culturing of peripheral blood B-lymphocytes
Ltk mouse fibroblast cells transfected with the human Fc␥I I receptor (CD32L cells, obtained from the American Type Culture System) were cultured in RPMI 1640 supplemented with 5% FCS and 2% HAT. After irradiation (70 Gy) CD32L cells were seeded 2 × 10 5 per well in 24-well flat bottom culture plates (Costar, Cambridge, MA, USA) and incubated overnight in a fully humidified 5% CO 2 atmosphere at 37°C. B cells were resuspended in culture medium consisting of IMDM (Gibco, Grand Island, NY, USA) supplemented with 5% heatinactivated FCS, 50g/ml human transferrin (Behringwerke, Mannheim, Germany), 5 g/ml bovine insulin (Sigma, St Louis, MO, USA), 0.5% human serum albumin (CLB, Amsterdam, The Netherlands), 0.01 mM ␤-mercaptoethanol (Sigma) and human recombinant IL-4 (a gift of Dr J Banchereau, Schering Plough, Dardilly, France) at a final concentration of 50 ng/ml. 75 × 10 4 B-lymphocytes in 1 ml culture medium were seeded upon the CD32L cells. Anti-CD40 MoAb 89 (a gift of Dr J Banchereau) was added at a final concentration of 0.5 g/ml. Cells were collected and cryopreserved after a 4 day culture period. 
Expression of IgH and IgL chains
Preparation and isolation of paraprotein Fab and polyclonal donor Ig
Ig was isolated from 5 ml patient serum (IgG concentration 18-62 mg/ml) or 50 ml donor serum using separate equilibrated immobilized protein G (Pierce, Rockford, IL, USA) columns and paraprotein Fabs were prepared using the Fab preparation kit (immobilized papain) according to the manufacturer's (Pierce) protocol. Undigested Ig and Fc fragments were removed by affinity chromatography with protein A-sepharose (Pierce). Immunoblotting with polyclonal rabbit antibodies against human IgG/A/M (DAKOPATTS) or polyclonal rabbit antibodies against human kappa or lambda light chains (DAKOPATTS) revealed less than 0.1% Fc or intact Ig contamination in the Fab preparations.
Phage libraries and selection procedures
For selection of anti-idiotypic reagents we used the 'single pot' Nissim phage library 13 containing over 10 8 clones expressing different single chain (V H -V 3 ) Fb chains. This phage repertoire was incubated for 1 h at room temperature with 2 mg polyclonal donor Ig in 2 ml incubation volume. The total mixture was then panned for binders using maxisorp immunotubes (Nunc, Kamstrup, Denmark) coated with 10 g/ml patient Fab in PBS overnight at room temperature. The library was subjected to four rounds of this selection procedure.
Screening of selected clones
Ninety-five individual ampicillin-resistant colonies of E. coli TG-1 were analyzed for phagemid presence by PCR using pHENSEQ: CTATGCGGCCCCATTCA and LMB3: CAGGAAA-CAGCTATGAC primers. PCR products were digested with BstNI to generate restriction patterns that are insert specific. These 96 colonies were grown and soluble scFv fragments were induced with 1 mM isopropyl ␤-D-thiogalactoside (IPTG; Gibco) as described in Marks et al. 16 The presence of soluble myc tagged scFv in culture medium was detected with a mouse anti-myc MoAb 9E10 17 in a dot blot assay. The binding of soluble scFv to patient Fabs, polyclonal donor Ig or BSA coated in maxisorp plates (Nunc) was detected with 9E10 17 MoAb in an ELISA procedure.
Purification of scFv
Phagemid was isolated from 5 ml cultures of bacteria expressing scFv. The scFv insert was released from the phagemid vector using NcoI and NotI restriction enzymes. pUC119Sfi/NotmycHis6 and pUC119Sfi/NotHis6vsv were digested with NcoI and NotI. Inserts were gel purified and ligated into gel-purified digested vectors. 15 The pUC119Sfi/NotmycHis6 and pUC119Sfi/NotHis6vsv clones encoding anti-Id and control scFv were grown in 0.5 l cultures. Expression of scFv was induced with IPTG as described by de Bellis and Schwartz. 18 ScFv were purified from bacterial periplasmic fractions using immobilized metal chelate affinity chromatography. 19, 20 The purification of scFv was monitored using SDS-PAGE under nonreducing conditions and silver staining of separated proteins. Concentrations of purified scFv were determined by measuring absorption at 280 nm in a spectrophotometer and comparison with molecular weight marker concentrations using SDS-PAGE.
FCM with anti-Id scFv
Cryopreserved BM samples containing plasma cells were thawed and fixed for 45 min at room temperature using Ortho permeafix (Ortho). ScFv in PBS or crude bacterial supernatant were added and the mixture was incubated for 30 min at 4°C. ScFv were detected through a 30 min incubation at 4°C with 0.02 mg/ml anti-myc antibody (9E10) or 0.02 mg/ml anti-vsv antibody (clone P5D4; Boehringer, Mannheim, Germany). Bound scFvs were detected using 1:50 diluted goat antimouse (FabЈ) 2 -FITC (American Qualex, San Clemente, CA, USA) and FCM. Background fluorescence was measured using irrelevant scFvs and PBS.
Results
Selection and characterization of anti-Id scFv directed against the M-portein idiotype
To obtain tumor clone-specific reagents we first isolated and purified M-protein Fab fragments from three myeloma patients. These Fab fragments were coated in tubes. To select for specific anti-idiotypic single chain Fv bearing phages directed against the myeloma M-protein we panned the Nissim phage library 13 against the coated M-protein Fab fragments in the presence of soluble polyclonal immunoglobulin as a competitor. After four rounds of this panning procedure we screened 95 individual (phage producing) bacterial clones using phagemid primers. We detected full length V H -V L in 91-94 clones indicating that the majority of phages selected carried complete single chain Fv structures. BstNI restriction enzyme digestion of the full length V H -V L inserts (ie fingerprinting) revealed 10-26 clones differing in V H insert ( Table 1 ). The selected bacterial clones were induced to produce soluble scFv and dot blotting showed that all culture supernatants contained significant amounts of scFv (results not shown). We found that 2-7 different soluble scFv bound specifically to patient Fab preparations and not to polyclonal donor Ig in an ELISA ( Table 1 ). The six clones (T3, T7, T13, T15, V19 and V22) that specifically reacted with Fab fragments of patients 1 or 2 were further characterized.
Detection of patient plasma cells using anti-Id scFvs
We tested the reactivity of the selected anti-Id scFvs with patient myelomatous plasma cells. Using fixed patient BM samples we were able to show that crude bacterial culture supernatants containing low amounts of soluble scFv specifically stained lambda-positive plasma cells (results not shown). We tried to enhance specific staining intensity using higher scFv concentrations or detection tags with lower background staining. Therefore, we subcloned the selected anti-Id and control scFvs in vectors encoding myc/his6 tags and his6/vsv tags. The his6 tags enable bulk purification of scFv from bacterial periplasmic fractions using immobilized metal chelate affinity chromatography. 20 Figure 1 shows that scFv can be purified to over 99% purity from a complex mixture of bacterial periplasmic proteins with IMAC. We incubated BM of patients 1 and 2 with scFv (concentrations ranging from 0.07 g/ml to 35 g/ml). Maximal staining of myelomatous plasma cells with minimal background staining of other BM cells was found at approximately 0.8 g/ml for five out of six scFv. At the highest concentration tested (35 g/ml) incubation of patient bone marrow with anti-idiotypic scFv T15 or control scFv T1 showed no detectable staining of plasma cells over background (results not shown). Staining intensity of patient myelomatous plasma cells with anti-idiotypic scFv T3, T7, T13 (for patient 1 bone marrow samples) and V19 and V22 (for patient 2 bone marrow samples) was comparable to commercially available polyclonal light chain antibodies ( Figure 2 and Table 2 ).
Comparison of myc tag with viral stomatitis virus tag for the detection of scFv binding
Since myc is an endogenous protein that is highly expressed in myeloma plasma cells using part of the myc protein as a scFv tag might result in high background staining of cells. We compared the detection of scFv binding and background staining of fixed patient bone marrows using anti-myc tag anti-
Figure 1
SDS-PAGE (4-12% gradient) analysis of single chain Fvs purified from crude bacterial periplasmic fractions using immobilized metale chelate affinity chromatography. Proteins were silver stained and protein size (indicated on the left) and concentration was estimated using molecular weight protein markers.
Figure 2
Flow cytometric detection of plasma cells in myeloma bone marrow using anti-idiotypic single chain Fvs directed against patient M-proteins. Bone marrow of patient 1T (a-c; e-g) containing approximately 37% plasma cells was fixed (Ortho) and stained with anti-kappa-
FITC (a) or anti-lambda-FITC (e). Anti-idiotypic single chain Fvs binding to M-protein Fab fragments of patient 1T (T3, T7) reacted with patient 1 plasma cells (f, g) not with patient 2 plasma cells (h). ScFvs binding to M-protein Fab fragments of patient 2V (V19) reacted with patient 2 plasma cells (d) not with patient 1 plasma cells (c). For determination of background reactivity bone marrow was incubated with PBS (not shown) or irrelevant control scFv (b). ScFv binding was detected with anti-myc antibodies 9E10 and goat anti-mouse FITC.
Table 2
Staining of myeloma cell lines, myeloma bone marrow samples donor plasma cells, donor B-lymphocytes and cultured B-lymphocytes with anti-idiotypic scFvs and anti-heavy and light chain polyclonal F(ab)s IgM  IgA  No scFy  T1  T3  T7  T13  T15  V19 bodies (for T1-, T7-and V19-myc/his6) and anti-viral stomatitis virus (vsv) tag antibodies (for T1-, T7-and V19-his6/vsv). Vsv and myc anti-idiotypic scFv showed comparable binding to patient Fab in ELISA (results not shown). Although overall background reactivity as determined with irrelevant control scFv T1 was higher with myc-tagged scFv, discrimination of plasma cells in patient bone marrow samples was not improved using vsv-tagged scFv (Figure 3) .
Kappa Lambda IgG
Specificity of anti-idiotypic scFvs
We tested the anti-Id scFv that showed strong reactivity with patient myelomatous plasma cells for cross-reactivity with other Ig idiotypes. Figure 2 and Table 2 show that scFv (T3, T7 and T13), selected for binding to Fab fragments from serum of patient 1 and reactive with myelomatous plasma cells of patient 1, did not cross-react with myelomatous plasma cells of patient 2, and scFv (V19 and V22), selected for binding to Fab fragments isolated from serum of patient 2, reacted with myelomatous plasma cells of patient 2 not with myelomatous plasma cells of patient 1, although the myelomatous plasma cells of both patients expressed identical Ig isotypes and comparable Ig levels. Binding of the anti-Id scFv with myeloma cell lines was comparable to background binding of control scFvs (T1), although six out of nine cell lines expressed both IgH and IgL chains and Ig levels of two of those cell lines were comparable with Ig levels in patient myelomatous plasma cells ( Table 2) .
As a control we tested the reactivity of the anti-Id scFv with polyclonal donor plasma cells and polyclonal cultured donor B-lymphocytes. Polyclonal plasma cells were selected from donor BM containing 0.5% plasma cells (Figure 4a ). We enriched for normal plasma cells using a mouse MoAb B-B4 (reactive with syndecan 1), specifically recognizing plasma cells among hematopoietic cells. 21 B-B4-labelled cells were selected with goat anti-mouse magnetic beads (Figure 4c ). As a second purification step, we flow sorted cells with high expression of CD38 and B-B4 from the B-B4-enriched fraction resulting in a 98% pure plasma cell fraction (Figure 4d ), confirmed by morphological evaluation of cytospin preparations. The majority of these plasma cells were of IgG (54%) or IgA (44%) isotype (Figure 5d and Table 2 ).Immunomagnetic beads were used to isolate CD19 expressing B-lymphocytes from peripheral blood of donors. Culturing of these B-lymphocytes with CD32L cells in the presence of anti-CD40 and IL4 induced proliferation and an isotype switch towards IgG (22%) and IgA (10%) expressing B cells (Table 2 ). K/ ratio of both plasma cells and cultured B-lymphocytes (Table 2) suggested polyclonality. We amplified the hypervariable region of the Ig heavy chain gene rearrangements by CDR3-PCR and subsequent analysis by denaturing PAGE proved polyclonality of the isolated donor plasma cells and cultured B-lymphocytes (results not shown). Reactivity of polyclonal plasma cells and polyclonal cultured B cells with anti-idiotypic scFv was comparable with the background reactivity of cells with irrelevant control scFvs ( Figure 5 and Table 2 ). These experiments prove the anti-idiotypic nature of our selected scFvs.
Sensitivity of anti-idiotypic scFvs
To test if anti-Id scFv can be used to detect low percentages of clonal tumor cells in a background of normal cells we diluted patient 2 BM containing 30% of myelomatous plasma cells in normal donor BM or in the myeloma cell line UM1 expressing high levels of IgG kappa. Figure 6 shows that we were able to detect 0.05% clonotypic plasma cells in a background of other bone marrow cells (Figure 6a ) or UM1 (Figure 6b ) using flow cytometry. 
Discussion
Anti-idiotypic antibodies that discriminate immunoglobulin idiotype expressing B cells from normal cells can be used to purge malignant B cells from autologous grafts and to treat B-lymphoma patients. [22] [23] [24] [25] Low specificity of 'anti-idiotypic' antibodies developed by immunizing rabbits or mice with antigen hampers their use in the study and eradication of idiotype-positive B cells in B cell malignancies. In a largescale study Kiyotaki et al 8 showed that 36 out of 39 conventional anti-Id Ab reacted with more than 0.1% of plasma cells isolated from tonsils of healthy persons. In this study, we selected single chain Fv bearing phages specifically directed against the M-protein idiotype of myeloma patients from a 'single pot' phage display library. To obtain reagents capable of specific detection of malignant cells we panned the phage library against purified myeloma M-protein Fab fragments in the presence of soluble polyclonal immunoglobulin as a competitor. Competitive selection procedures have been used successfully for selection of phages capable of discriminating between two highly homologous homeobox proteins. 26 The isolation of phages reactive with a defined difference between two otherwise identical protein mixtures 27 illustrates the potential of these competitive selection procedures. We selected 2-7 anti-Id single chain Fv bearing phage clones per selection. Using flow cytometry we have found that five out of six soluble anti-Id scFv specifically stained myelomatous plasma cells of one patient, not with the plasma cells of other myeloma patients, nor with myeloma cell lines expressing high levels of isotype-matched Ig. ScFvs were incubated with donor plasma cells and cultured B-lymphocytes to assess the scFv reactivity with cell populations containing multiple idiotypes. We showed with PCR analysis that these populations were polyclonal for one of the regions (CDR3) encoding the immunoglobulin idiotype. Anti-idiotypic scFv stained Ͻ0.3% of the cells and staining was always less than with control scFv, proving the anti-idiotypic nature of the selected scFv reagents.
In dilution experiments we were able to detect 0.05% of patient plasma cells in a background of donor BM cells or UM1 cells expressing high levels of immunoglobulin. The detection limit of this technique is dependent on the background reactivity with irrelevant scFv. In our experiments the background reactivity was generally between 0.5 and 0.01%. Lowering background reactivity might permit a more sensitive detection of myelomatous plasma cells. In initial experiments scFv were tagged with small stretches of the c-myc protein 11, 13 enabling their detection. Since expression of endogenous cmyc protein resulted in high background staining and obscured the detection of intracellular myc-tagged scFv we reasoned that using a viral tag might enable a more sensitive detection of scFv. Therefore, we subcloned our reactive anti-
Figure 6
Sensitivity of plasma cell detection using an anti-idiotypic scFv (V19). Bone marrow of patient 2V containing 30% plasma cells (ab1) was diluted in donor bone marrow (a6) or myeloma cell line UM1 (b6). The dilutions were fixed (Ortho) and incubated with anti-idiotypic scFv V19. ScFv binding was detected with anti-myc antibodies 9E10 and goat anti-mouse FITC and analyzed using flow cytometry.
Id scFv in vectors with viral stomatitis virus (vsv) tags. 28, 29 Although overall background reactivity of vsv-tagged scFv was lower than myc-tagged scFv, discrimination of plasma cells in patient bone marrow samples was not improved using vsvtagged scFv. This might be caused by variations in endogenous c-myc levels in hematopoietic subpopulations. High levels of c-myc protein and mRNA have been detected in activated malignant plasma cells 30, 31 and might aid in the discrimination between myc-scFv-positive plasma cells and myc-scFv-negative non-plasma cells. Our observation that plasma cells have more background myc fluorescence (determined in controls without scFv) than other BM cells supports this hypothesis. Current efforts to lower background activity are concentrated on the construction and use of directly labelled scFv.
To study the role of clonally related B-lymphocytes in the pathogenesis of multiple myeloma their isolation is imperative. PCR assays using allele-specific oligonucleotides (ASO) complementary to the unique IgH CDRIII sequence of the malignant clone are currently the most sensitive and specific assays for detection of malignant B-or plasma cells. Therefore, ASO-PCRs that are capable of detecting one malignant or clonally related cell in a background of 100 000 other cells have been used to evaluate minimal residual disease. 32, 33 Recently Cao et al 34 and Brown et al 35 showed that malignant plasma cells can be identified with in situ hybridization using fluorescent or enzyme-labelled ASO probes reactive with the IgH CDRIII region. Since fixation is a prerequisite for these techniques none of them allows the functional study of clonally related B cells. This study shows that anti-Id scFv can be used to detect one idiotype expressing plasma cell in a background of 2000 normal cells. The challenge ahead is the isolation of viable clonally related B cells using these anti-Ids.
